Charles River Laboratories International, Inc. (CRL) fair value analysis
S&P 500 · Updated 2026-10-19
CRL price how computed
Forward Fair Value verdict
OvervaluedCRL is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $301.79
- Sector
- Healthcare
- 12-month range
- $149.93–$310.77
- Market cap
- $14.5B
- From 52-week high
- -2.9%
- Shares outstanding
- 48.2M
- Rank in Healthcare by discount to fair value
- #108 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Charles River Laboratories International, Inc. provides drug discovery, development, and safety testing services for the pharmaceutical, biotechnology, and chemical industries. The company operates laboratories and facilities across North America, Europe, and Asia to support its clients' research and regulatory requirements.
CRL currently ranks #108 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $14.5B
- P/E (trailing)
- 30x
- Revenue (TTM)
- $4B
- Net margin
- -6.0%
- EPS (TTM)
- $9.90
- Gross margin
- 36.2%
- Debt / equity
- 1.07
- Revenue growth (3-yr avg)
- -0.7%
- Shares outstanding
- 48.2M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 58 · neutral
- 50-day average
- $288.88
- 200-day average
- $215.10
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+11.0%)
2026-03 ▲ beat (+5.6%)
2025-12 ▲ beat (+2.6%)
2025-09 ▲ beat (+4.7%)
2025-06 ▲ beat (+22.4%)
2025-03 ▲ beat (+13.0%)
2024-12 ▲ beat (+5.1%)
2024-09 ▲ beat (+7.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 2 hold · 1 sell (18 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $316
- Target vs last price
- +4.7%
What our data shows for CRL
- Our model validated 17 trailing price-to-earnings windows for CRL, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $149.93–$310.77.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CRL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CRL news
TickrTrends' derived news-sentiment signal for CRL is currently leaning positive, computed from recent coverage.
- A Look at Charles River Laboratories International Inc (CRL) After 9.3% Gain -- GF Value $194.24 vs Price $344.87 (gurufocus.com, 2026-10-21)
TickrTrends take: Charles River Laboratories stock has risen significantly, but TickrTrends currently assesses it as overvalued relative to its fundamental metrics. The gap between the GF Value estimate and the current trading price suggests the stock may be priced above levels supported by its underlying business performance. Investors focused on valuation should monitor whether the company's earnings growth justifies the current premium, particularly given the competitive dynamics within the Healthcare sector. - Charles River Laboratories International Inc (CRL): What a GF Score of 63 Says About the Stock (gurufocus.com, 2026-10-21)
TickrTrends take: Charles River Laboratories International Inc operates in the Healthcare sector and currently trades at a valuation that TickrTrends rates as Overvalued. A GF Score of 63 suggests moderate quality fundamentals, which when paired with an elevated valuation multiple, indicates the stock may not offer attractive risk-reward dynamics for value-oriented investors at current prices. Investors focused on valuation metrics should monitor whether CRL's fundamental performance can justify its premium pricing or if mean reversion toward its sector peers becomes more likely. - Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued (gurufocus.com, 2026-10-20)
TickrTrends take: Charles River Laboratories has experienced a recent price increase, yet TickrTrends' valuation analysis continues to indicate the stock trades above its intrinsic value estimate. The company's Healthcare sector position and the persistent overvaluation assessment suggest that investors focused on valuation metrics should monitor whether the stock's valuation gap narrows through either price adjustment or improved financial performance. A valuation-conscious investor would need to see fundamental improvements or multiple compression before the stock aligns with intrinsic value estimates.
More CRL news
- AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects (gurufocus.com, 2026-10-20)
- Charles River Laboratories (CRL) -- Biopharma Demand Drives Growth | Ariel Fund Q3 2026 (gurufocus.com, 2026-10-17)
- ETFs Are Net Sellers of Charles River (CRL) on Wednesday (gurufocus.com, 2026-10-16)
- A Look at Charles River Laboratories International Inc (CRL) After 7.1% Gain -- GF Value $194.24 vs Price $310.77 (gurufocus.com, 2026-10-05)
- CRL Reinstated by UBS -- Price Target Announced at $357.00 (gurufocus.com, 2026-09-30)
- UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook (gurufocus.com, 2026-09-30)
What people are saying
Follow the CRL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CRL stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CRL is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is CRL's TickrTrends verdict?
CRL's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does CRL compare to other Healthcare stocks?
CRL ranks #108 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is CRL overbought or oversold?
CRL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CRL report earnings next?
CRL's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does CRL usually beat earnings estimates?
Over its last 8 reported quarters CRL beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CRL?
Of 18 analysts covering CRL, 15 rate it a buy, 2 a hold and 1 a sell - buy-leaning, with a consensus price target of $316 (+4.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
CRL vs ALKS · CRL vs AZTA · CRL vs CDNA · CRL vs DGX · CRL vs GILD